2030 Educators providing Courses

Pcsk9 Education And Research Forum

pcsk9 education and research forum

Alcester

Reducing low density lipoprotein (LDL) cholesterol is the priority in managing patients with severe dyslipidaemia (cholesterol abnormality) and at high risk of cardiovascular (CV) death and disability. Yet even when treated with potent statins, many patients fail to achieve LDL-cholesterol targets and therefore their risk of accelerated atherosclerosis and CV death remains high. This problem is particularly critical in patients with familial hypercholesterolaemia (FH) (the most commonly occurring genetic condition in the world). People with FH typically have very high LDL cholesterol levels on treatment, and consequently, are at very high risk of premature and sudden CV death, myocardial infarction and stroke. Additionally, some patients are unable to tolerate statins – particularly at higher doses – and, therefore, do not achieve LDL-cholesterol goals. What is the importance of PCSK9? Discovered in 2003,1 PCSK9 is a protein made by the liver which increases the removal of LDL receptors from the surface of liver cells. These LDL receptors are critically important in removal of serum LDL-cholesterol from the circulation. People with so-called ‘gain of function’ PCSK9 mutations over-express PCSK9, and therefore have very high plasma levels of LDL cholesterol and are at very risk of atherosclerosis and CV mortality and morbidity.2 In contrast, people with so-called ‘loss of function’ PCSK9 mutations, have very LDL cholesterol levels and reduced risk for heart disease.3 What is PCSK9 inhibition? Different approaches to lowering PCSK9 are now licensed. These include fully human monoclonal antibodies (alirocumab, evolocumab) and a small-interfering RNA therapy (inclisiran). Trials show that these PCSK9 inhibitors reduce LDL cholesterol levels by about 50-60 percent - a significantly greater effect than that achieved with currently available therapies – either when given alone or in combination. These LDL cholesterol lowering effects have been consistently across a broad group of patients, including those with familial hypercholesterolaemia in clinical trials.4 Which clinical settings will benefit from the availability of PCSK9 inhibitors? These treatments offer the potential to reduce cardiovascular risk in patients whose clinical needs cannot be satisfied by current therapy. These include: Patients with familial hypercholesterolaemia – an inherited disorder of lipid metabolism with a very high risk of early CV death or morbidity, if not diagnosed or treated early Patients who cannot tolerate statins, who therefore remain at high risk of CV events such as heart attacks and strokes Patients with established heart disease who have not achieved LDL-cholesterol goals despite current therapies

The London Education & Art Foundation

the london education & art foundation

London

Total 30 years of experience in management, of which half of this overlaps in the world of academia. He is experienced in managing multicultural teams and has delivered some high-level consultancy projects in the UK and overseas for the commercial and public sectors. Paul is on the Advisory Board of UK universities, UK social enterprises and charitable organisations. His interests are in the areas of Arts, he is a fellow of the Royal Society of Arts (FRSA) and has held numerous art exhibitions in London. Role: Chairman of Trustees, Head of Partnerships and Memberships. Mr Andrew Trustee FAIA, FCIPD, FRSA - Expert International Accountant and Legal Advisor Total 45 years in UK and International public practice as an accountant and legal services provider serving in the charitable, public and art sectors as a trustee, chairman, director and treasurer. A Liveryman of the City of London and past President of the Association of International Accountants (UK) and the Association de Brecourt (Belgium). A member of the International Bar Association and International Fiscal Association. Role: Trustee, Governance, Compliance and Financial Management. Degard RCA, FRSA Trustee International Artist, MA (Edin), Phd Research Fine Art Degard is a pioneering British 'Painter of Auras', writer, researcher, curator and founder of the genre Contemporary Visionary art. Degard has exhibited extensively in the UK and internationally: The Royal College of Art, Museum Alzubair, Oman, in New York, London and at Saatchi Art. Degard has written four books, is a committee member of The Colour Group, a property developer and a Fellow of The Galileo Commission for the Scientific and Medical Network. She has a Masters in Politics from Edinburgh University and is completing her doctorate in Fine Art in London. Role: Trustee, Head of Media and Events. Ambassadors of LEAF Miss Sophie Ambassador - Arts, Culture, Events. United Kingdom Oxford Graduate in Classics Sophie is a recent Oxford graduate of Classics. Having studied at Oxford for four years, she specialised in Greek and Roman art and archaeology, and has attended seminars, workshops, and focus groups on artwork from antiquity at the Ashmolean Museum, the British Museum and the British Academy. Sophie also has experience working in marketing and advertising and has worked as a gallery invigilator at galleries around London. Mr Ahmed Ambassador - Arts, Culture, Events. Middle East/North Africa (MENA) With more than 10 years of experience in the field of management and business, Ahmed has contributed in building professional teams, and developing strategies in one of the largest companies the Middle East. His interests relate to international and Islamic culture and the arts, and is looking forward to working with professional partners between overseas organisations and the LEAF Foundation. He is also a member of several institutions including: The Royal united services institute (RUSI) The Royal Institute of International Affairs (Chatham House) The British academy of management The Institute of Directors (IoD) The Chartered Management Institute (CMI) Miss Emilia Ambassador - Culture, Education, Events. London & Eastern Europe With over 13 years of experience in sales, business and NLP, Emilia has provided high-level strategies for team building and management, excellent customer service and sales enhancement for UK enterprises and international multi-level marketing organisations. She is proficient in NLP and working with multicultural communities and has held self-development and mentoring workshops in various parts of London. Emilia is on the Governing and Advisory Board of London secondary schools to encourage and ensure children's learning and development. Her interests are in the areas of Arts and self-development with the aim to support individuals and sole entrepreneurs into their personal and business development journey. Miss Summer Ambassador - Arts, Fashion, Events. Shanghai & China Summer has an MBA in global Luxury management and graduated from Paris. She is in charge of the fashion department of Paris International Young Artists Association, and the key account manager of Chanel. During her stay in the UK, Summer won a number of national design competitions. As a winner of Chatsworth House design competition, she was chosen by the Douches of Devonshire. She has professional bespoke and fashion design background and luxury management experience. Mr Satoshi Ambassador - Arts, Culture, Events. L.A. USA Satoshi is the CEO of Life is Tech! USA. It is a Los Angeles-based EdTech startup best known as the creators of the acclaimed coding education program, Disney Codeillusion. With over 17 years of experience in international business, with a focus on the U.S., UK and Japan, delivering life-changing opportunities to as many people as possible, is what Satoshi lives for. He holds an MBA from Stanford University. He is a Mentor for BLAST School, an incubation program that supports high school students with ideas for solving social issues. Satoshi is also a Chartered Member of the Securities Analysts Association of Japan Miss Mika Ambassador - Education, Culture, Events. Osaka Japan Mika is a Business and